tiprankstipranks
CG Oncology, Inc. (CGON)
NASDAQ:CGON
US Market
CGON
CG Oncology, Inc.
RESEARCH TOOLSreports
Want to see CGON full AI Analyst Report?

CG Oncology, Inc. (CGON) Stock News & Sentiment

316 Followers
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
5d ago
CGON
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
Premium
Ratings
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
12d ago
CGON
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
Premium
Ratings
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
13d ago
CGON
Alec Stranahan Reiterates Buy on CG Oncology, Maintains $83 Price Target on Cretostimogene’s Best-in-Class Potential and Upcoming PIVOT-006 Catalyst
Premium
Ratings
Alec Stranahan Reiterates Buy on CG Oncology, Maintains $83 Price Target on Cretostimogene’s Best-in-Class Potential and Upcoming PIVOT-006 Catalyst
13d ago
CGON
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
Premium
Company Announcements
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
1M ago
8K
CGON
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
Premium
Ratings
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
2M ago
CGON
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
Premium
Ratings
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
3M ago
CGON
More CGON News >

CGON News on the Web

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
MarketBeat
Bullish
CG Oncology and SUO-CTC Support Novel Bladder Cancer Research With Annual $50,000 Fellowships
Market Chameleon
Neutral
CG Oncology initiated with a Peer Perform at Wolfe Research
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYRE)
TipRanks News
Bullish
Wedbush Remains a Buy on CG Oncology, Inc. (CGON)
TipRanks News
Bullish
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
TipRanks News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON)
TipRanks News
Bullish
Why CG Oncology Stock Is Sliding Despite Good News
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CGON
Sector Average
Media Buzz
This Week7 articles
Weekly Average7.75 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CGON’s Media Buzz Sentiment?
7 articles about CGON were published this week. In an average week, 7.75 articles are published.
    What is CGON’s weekly average amount of articles?
    In an average week, 7.75 articles about CGON are published.
      What is CGON’s News Sentiment?
      100% of articles about CGON were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week